Related Experiment Video

Updated: Mar 13, 2026

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

3.5K

[Pulmonary hypertension associated with left heart disease: recommendations of the Cologne Consensus Conference 2016]

S Rosenkranz, I M Lang, R Blindt

    Deutsche Medizinische Wochenschrift (1946)
    |October 21, 2016
    PubMed

    Insights

    The 2015 European Guidelines for pulmonary hypertension (PH) need specific German implementation, especially for PH due to left heart disease. This consensus addresses practical issues and data gaps for better patient care.

    Area of Science:

    • Cardiology
    • Pulmonology
    • Medical Guidelines

    Background:

    • The 2015 European Guidelines for Pulmonary Hypertension (PH) are applicable in Germany but offer limited detail on PH due to left heart disease (PH-LHD).
    • Despite insufficient evidence, treatments for pulmonary arterial hypertension (PAH) are being used for PH-LHD, raising concerns about resource allocation and evidence-based practice.
    • PH-LHD is common and significantly impacts morbidity and mortality in patients with left heart disease, highlighting an unmet need for targeted therapies.

    Purpose of the Study:

    • To address practical and controversial issues regarding the implementation of the 2015 European PH Guidelines in Germany.
    • To provide a detailed commentary and update on PH management, particularly for PH-LHD.
    • To summarize the results and recommendations from a 2016 Consensus Conference on PH in Germany.

    Main Methods:

    • A consensus conference was held in Cologne, Germany, in June 2016, involving PH working groups from the German Society of Cardiology, German Society of Respiratory Medicine, and German Society of Pediatric Cardiology.
    • Working groups were established to address specific issues, including a dedicated group for PH associated with left heart disease.
    • The article summarizes the findings and recommendations generated by these working groups.

    Main Results:

    • The guidelines require specific consideration for German implementation, especially concerning PH-LHD.
    • There is a need for evidence-based treatment strategies for PH-LHD, moving beyond the off-label use of PAH therapies.
    • Novel data and practical considerations necessitate an update and detailed commentary on the existing European guidelines.

    Conclusions:

    • The practical implementation of European PH guidelines in Germany requires addressing specific issues related to PH-LHD.
    • There is an urgent need for targeted therapies and evidence-based treatment approaches for PH-LHD.
    • A detailed commentary and potential update to the guidelines are necessary to reflect current data and clinical needs.

    More Related Videos

    Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat08:34

    Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

    Published on: November 18, 2018

    7.8K
    Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets08:08

    Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

    Published on: May 11, 2015

    14.7K

    Related Concept Videos

    Pulmonary Hypertension: Classification and Pathogenesis01:30

    Pulmonary Hypertension: Classification and Pathogenesis

    Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
    There are various classifications for PH, each relating to different underlying causes and also...
    764
    Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

    Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

    Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
    Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
    714
    Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

    Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

    Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
    Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
    Primary Symptoms of COPD:
    4.0K
    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

    Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
    These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
    579
    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

    Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
    Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
    682
    Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

    Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

    Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
    614